RF Lafferty Starts Coverage On Enable Midstream Partners (ENBL) with $19 Target; Heat Biologics (HTBX)’s Sentiment Is 0.78

December 6, 2017 - By Migdalia James

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company has market cap of $15.03 million. The firm develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. It currently has negative earnings. The Company’s product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer.

Among 11 analysts covering Enable Midstream Partners (NYSE:ENBL), 5 have Buy rating, 2 Sell and 4 Hold. Therefore 45% are positive. Enable Midstream Partners has $23 highest and $6 lowest target. $15.40’s average target is 2.67% above currents $15 stock price. Enable Midstream Partners had 31 analyst reports since July 22, 2015 according to SRatingsIntel. Barclays Capital maintained Enable Midstream Partners, LP (NYSE:ENBL) rating on Thursday, March 31. Barclays Capital has “Equal-Weight” rating and $10 target. The firm has “Neutral” rating by Goldman Sachs given on Monday, September 19. The firm has “Equal-Weight” rating given on Monday, November 9 by Barclays Capital. RBC Capital Markets maintained Enable Midstream Partners, LP (NYSE:ENBL) on Thursday, November 5 with “Sector Perform” rating. As per Thursday, March 17, the company rating was upgraded by Credit Suisse. Stifel Nicolaus initiated Enable Midstream Partners, LP (NYSE:ENBL) on Wednesday, January 18 with “Hold” rating. Barclays Capital downgraded the shares of ENBL in report on Monday, June 20 to “Underweight” rating. The company was maintained on Sunday, August 13 by RBC Capital Markets. On Monday, May 9 the stock rating was maintained by Barclays Capital with “Equal-Weight”. The stock of Enable Midstream Partners, LP (NYSE:ENBL) earned “Buy” rating by Citigroup on Monday, October 19.

Enable Midstream Partners, LP owns, operates, and develops midstream energy infrastructure assets in the United States. The company has market cap of $6.49 billion. It operates in two divisions, Gathering and Processing, and Transportation and Storage. It has a 18.05 P/E ratio. The Gathering and Processing segment provides natural gas gathering, processing, and fractionation services in the Anadarko, Arkoma, and Ark-La-Tex basins, as well as crude oil gathering services in the Bakken Shale formation of the Williston Basin for its producer customers.

The stock increased 1.56% or $0.23 during the last trading session, reaching $15. About 32,814 shares traded. Enable Midstream Partners, LP (NYSE:ENBL) has risen 21.66% since December 6, 2016 and is uptrending. It has outperformed by 4.96% the S&P500.

Analysts await Enable Midstream Partners, LP (NYSE:ENBL) to report earnings on February, 20. They expect $0.19 EPS, up 35.71% or $0.05 from last year’s $0.14 per share. ENBL’s profit will be $82.18 million for 19.74 P/E if the $0.19 EPS becomes a reality. After $0.24 actual EPS reported by Enable Midstream Partners, LP for the previous quarter, Wall Street now forecasts -20.83% negative EPS growth.

Sabby Management Llc holds 0.08% of its portfolio in Heat Biologics, Inc. for 2.02 million shares. Franklin Street Advisors Inc Nc owns 60,500 shares or 0.01% of their US portfolio. Moreover, Bank Of New York Mellon Corp has 0% invested in the company for 13,399 shares. The New York-based Blackrock Inc. has invested 0% in the stock. Deutsche Bank Ag, a Germany-based fund reported 200 shares.

The stock decreased 1.64% or $0.01 during the last trading session, reaching $0.42. About 89,538 shares traded. Heat Biologics, Inc. (HTBX) has risen 35.57% since December 6, 2016 and is uptrending. It has outperformed by 18.87% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com